Results 181 to 190 of about 53,202 (260)

Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies. [PDF]

Obesity (Silver Spring)
Garvey WT, Rosenstock J, Bays HE, Denham D, Kohli A, Haines M, Jones C, Kwan E, Castelloe E, Marmon T, Kuriakose E, Nelson C.   +11 more
europepmc   +1 more source

GLP‐1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9377-9384, October 2026.
ABSTRACT Aims Existing evidence regarding the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and risk of melanoma and non‐melanoma skin cancer (NMSC) is inconclusive. This study aimed to assess the association between GLP‐1RA initiation and risks of melanoma and NMSC versus sodium–glucose cotransporter 2 inhibitors (SGLT2is ...
Huilin Tang, Bingyu Zhang, Ying Lu, Ting Zhou, Yiwen Lu, César A. Briceño, Jiali Han, Yong Chen   +7 more
wiley   +1 more source

Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use. [PDF]

J Endocr Soc
Ayo-Ajibola O, Jung T, Razura DE, Gallagher TJ, Lin ME, Angell TE, Kwon DI.   +6 more
europepmc   +1 more source

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9633-9643, October 2026.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain, Pierre Bel Lassen, Christine Bellanné‐Chantelot, Marie Christine Vantyghem, Hippolyte Dupuis, Tiphaine Vidal‐Trecan, Nicolas Chevalier, Danièle Dubois‐Laforgue, Sophie Lamothe, Camille Vatier, Orianne Villard, René Valéro, Claire Briet, Corinne Vigouroux, Cécile Ciangura, Chloé Amouyal   +15 more
wiley   +1 more source

GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites. [PDF]

Nutrients
Gong B, Shi Z, Qi J, Wang F, Chen G, Su H.   +5 more
europepmc   +1 more source

Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study

HIV Medicine, Volume 27, Issue 10, Page 1710-1714, October 2026.
Abstract Objectives We have shown that semaglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), is a highly effective therapy for metabolic dysfunction‐associated steatotic liver disease (MASLD) in people with HIV (PWH). The OWLiver® metabolomics algorithms allow non‐invasive MASLD severity staging without liver biopsy, but the use of ...
Jordan E. Lake, Douglas W. Kitch, Amy Kantor, Rebeca Mayo, Pablo Belaunzaran‐Zamudio, Carl J. Fichtenbaum, Todd T. Brown, Kathleen E. Corey, Fred Sattler, Kristine M. Erlandson   +9 more
wiley   +1 more source

Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment. [PDF]

Front Endocrinol (Lausanne)
Milani I, Parrotta ME, Chinucci M, Franzò E, Gintoli E, Franco F, Sbraccia P, Guglielmi V, Capoccia D.   +8 more
europepmc   +1 more source

Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1695-1707, October 2026.
Liraglutide reverses hyperglycemia‐induced metabolic reprogramming in vascular smooth muscle cells, restoring mitochondrial function and AMPK/PGC‐1α signaling while suppressing mTOR activation and HIF‐1α accumulation. These changes attenuate extracellular matrix remodeling, reduce atherosclerotic plaque burden, and improve plaque stability in diabetic ...
Kun Zhu, Hanxiu Liu, Ni He, Haoyang Wang, Jing Liu, Qinhu Zhang, Zhongwei Liu   +6 more
wiley   +1 more source

GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. [PDF]

Nutrients
Bruna-Mejias A, Valenzuela-Fuenzalida JJ, Oyanedel G, Figueroa-Puig J, Cabezas-Salgado JJ, Orellana-Donoso M, Cifuentes-Suazo G, Loro-Ferrer JF.   +7 more
europepmc   +1 more source

GLP-1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study. [PDF]

BJUI Compass
Kwon S, Wardrop F, Gonzalez D, Ryan F, Khutsishvili L, Turner R, Deameh MG, Whalen MJ.   +7 more
europepmc   +1 more source